Drugs / ATI-2231
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05791474 | Nov 2023 → Jun 2025 | high grade malignant neoplasm | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATI-2231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05791474 ↗ |
| Route | Oral | “20 mg by mouth twice per day” NCT05791474 ↗ |